Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InotivSTU:BS50 Cyclically Adjusted PS Ratio is 0.00 as of Aug. 08, 2026. The stock has 4 warning signs investors should review. Among 135 Medical Diagnostics & Research companies, Inotiv ranks worse than 740740% on this metric.
As of today (2026-08-08), Inotiv's current share price is €0.04. Inotiv's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €10.27. Inotiv's Cyclically Adjusted PS Ratio for today is 0.00.
The historical rank and industry rank for Inotiv's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Inotiv's highest Cyclically Adjusted PS Ratio was 14.19. The lowest was 0.01. And the median was 0.46.
STU:BS50's Cyclically Adjusted PS Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.94 * Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Inotiv's adjusted revenue per share data for the three months ended in Mar. 2026 was €2.937. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €10.27 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Inotiv (STU:BS50) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Inotiv Cyclically Adjusted PS Ratio Related Terms
Inotiv Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Inotiv's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:BS50 vs NSTM, PRPH, IDTA: Cyclically Adjusted PS Ratio Comparison
For the Diagnostics & Research subindustry, Inotiv's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inotiv Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Inotiv's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Inotiv's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.00 mean?
Inotiv (STU:BS50) has a Cyclically Adjusted PS Ratio of 0.00 as of Aug. 08, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Inotiv and its competitors. Over the past decade, Inotiv's Cyclically Adjusted PS Ratio has ranged from 0.01 to 14.19. According to the industry distribution chart, Inotiv ranks #999999 out of 135 companies in the Medical Diagnostics & Research industry.
Is Inotiv's Cyclically Adjusted PS Ratio too high?
Inotiv's current Cyclically Adjusted PS Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 14.19. Based on the distribution chart, Inotiv ranks #999999 out of 135 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Inotiv's Cyclically Adjusted PS Ratio compare to NSTM and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Inotiv ranks #999999 out of 135 companies for Cyclically Adjusted PS Ratio. This places Inotiv in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.94. Historically, Inotiv's own Cyclically Adjusted PS Ratio has ranged from 0.01 to 14.19 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PS Ratio among Medical Diagnostics & Research companies is 1.94, based on 135 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Inotiv and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PS Ratio is 1.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inotiv's current Cyclically Adjusted PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (STU:BS50) is currently considered Possible Value Trap. The stock's GF Value™ is €1.43, compared to a current price of €0.04 — trading 97.2% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Inotiv (STU:BS50), the current Cyclically Adjusted PS Ratio is 0.00 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:BS50 has been successfully added to your 
